Organon & Co.

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-16 pm EST			5-day change	1st Jan Change
8.760 ^USD	+0.69%		+7.88%	+22.18%

Jan. 17	Organon Announces Us Food and Drug Administration Approval of Supplemental New Drug Application Extending Time of Use of Nexplanon®? (Etonogestrel Implant) 68 Mg Radiopaque	CI
Jan. 16	Organon announces US FDA approval of supplemental new drug application extending duration of use of Nexplanon® 68 mg radiopaque	RE

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

Published on 11/07/2025 at 09:42 am EST

Dow Jones

Organon & Co.

+0.69%

Investor AB

-3.88%

By Dominic Chopping

STOCKHOLM--Medical device developer Laborie agreed to buy a specialist system developed to stop bleeding for up to $465 million from Organon.

Laborie is owned by Patricia Industries, a subsidiary of Swedish investment and holding company Investor AB.

Under the deal, Laborie will buy the Jada System for $440 million at closing plus up to a further $25 million contingent on certain 2026 revenue targets.

The Jada System is used to treat abnormal bleeding after childbirth and is currently used in more than 20 countries globally.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

11-07-25 0941ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ORGANON & CO.	8.760USD	+0.69%	+7.88%	2.28B
	INVESTOR AB	334.60SEK	-3.88%	-1.30%	116B

Latest news about Organon & Co.

Jan. 17	Organon Announces Us Food and Drug Administration Approval of Supplemental New Drug Application Extending Time of Use of Nexplanon®? (Etonogestrel Implant) 68 Mg Radiopaque	CI
Jan. 16	Organon announces US FDA approval of supplemental new drug application extending duration of use of Nexplanon® 68 mg radiopaque	RE
Jan. 08	Organon, Daiichi Sankyo Europe Sign Commercialization Deal for Nilemdo	MT
Jan. 08	Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo®? in France, Denmark, Iceland, Sweden, Finland and Norway	CI
Dec. 03	Organon & Co. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 10:00 AM
Nov. 17	Shanghai Henlius Biotech, Inc. and Organon Announce US FDA Approval of POHERDY®? (pertuzumab-dpzb) Biosimilar in the US	CI
Nov. 17	Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar	MT
Nov. 12	Washington's Drama Winds Down (For Now)
Nov. 12	Analyst recommendations: AT&T, Fortinet, AMD, Datadog, Wayfair…
Nov. 10	Organon & Co. Declares Quarterly Dividend on Common Stock, Payable on December 11, 2025	CI
Nov. 10	Organon & Co. Revises Earnings Guidance for the Full Year of 2025	CI
Nov. 10	Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 10	Organon & Co., Q3 2025 Earnings Call, Nov 10, 2025
Nov. 10	Organon & Co Q3 Adjusted Earnings, Revenue Rise; Trims 2025 Revenue Guidance	MT
Nov. 10	(OGN) Organon Expects Full Year 2025 Revenue Range $6.20B to $6.25B, vs. FactSet Est of $6.29B	MT
Nov. 10	Earnings Flash (OGN) Organon & Co. Reports Q3 Revenue $1.60B, vs. FactSet Est of $1.57B	MT
Nov. 10	Earnings Flash (OGN) Organon & Co. Posts Q3 Adjusted EPS $1.01 per Share, vs. FactSet Est of $0.94	MT
Nov. 10	Healthcare products maker Organon beats Q3 profit estimates, cuts FY forecast	RE
Nov. 08	Organon Announces New Data Show Early and Consistent Response to VTAMA Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those with Associated Comorbidities	CI
Nov. 07	Investor AB Unit Buys Obstetrics Medical Device System for $440 Million	MT
Nov. 07	Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon	DJ
Nov. 07	Organon to Sell Jada System to Laborie Medical Technologies	MT
Nov. 07	Patricia Subsidiary Acquires Jada System for Up to $465 Million	FW
Nov. 07	Organon announces agreement to divest its Jada system for up to $465 million to Laborie	RE
Nov. 07	Grace Puma Not to Stand for Re-Election as a Member of the Board of Director of Organon & Co	CI

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Employees

10,000

Sector

Pharmaceuticals

Calendar

Feb. 11 - Q4 2025 Earnings Release (Projected)

More about the company